Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $312000.0.

  • Voyager Therapeutics' Change in Account Payables fell 4378.38% to $312000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 84909.09%. This contributed to the annual value of $2.4 million for FY2024, which is 34864.86% up from last year.
  • Per Voyager Therapeutics' latest filing, its Change in Account Payables stood at $312000.0 for Q3 2025, which was down 4378.38% from -$830000.0 recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Change in Account Payables peaked at $6.0 million during Q1 2024, and registered a low of -$5.0 million during Q2 2024.
  • Over the past 5 years, Voyager Therapeutics' median Change in Account Payables value was $119000.0 (recorded in 2022), while the average stood at $78000.0.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 692777.78% in 2022, then tumbled by 1142777.78% in 2023.
  • Voyager Therapeutics' Change in Account Payables (Quarter) stood at -$18000.0 in 2021, then surged by 6927.78% to $1.2 million in 2022, then plummeted by 235.56% to -$1.7 million in 2023, then skyrocketed by 150.18% to $836000.0 in 2024, then plummeted by 62.68% to $312000.0 in 2025.
  • Its Change in Account Payables stands at $312000.0 for Q3 2025, versus -$830000.0 for Q2 2025 and -$1.4 million for Q1 2025.